FDA Approves New Imaging Agent for Prostate Cancer Detection

September 13, 2012

The Food and Drug Administration has approved the production and use of the imaging agent Choline C 11 for the detection of recurrent prostate cancer.

"Choline C 11 injection provides an important imaging method to help detect the location of prostate cancer in patients whose blood tests suggest recurrent cancer when other imaging tests are negative," noted Dr. Charles Ganley, director of the Office of Drug Evaluation IV in the FDA’s Center for Drug Evaluation and Research, in an FDA statement.